Which competitors are most likely after Keytruda’s exclusivity ends?
After Keytruda (pembrolizumab) exclusivity expires, the most likely competition will come from:
1) Other PD-1 inhibitors already sold in the same oncology settings, and
2) New or improved immunotherapy combinations that compete for the same indications and lines of therapy.
The most visible PD-1 competitors are Bristol Myers Squibb’s Opdivo (nivolumab) and Roche’s Tecentriq (atezolizumab), alongside other immuno-oncology drugs that can substitute for Keytruda in specific tumor types and treatment sequences. Coverage depends heavily on indication, line of therapy, biomarkers, and prior treatment history—so “who replaces Keytruda” varies by cancer.
Will biosimilars to Keytruda be able to enter?
Yes, biosimilars are the main “direct” path to lower-cost versions once Keytruda’s market exclusivity and relevant patent protections are fully cleared. In practice, biosimilar entry timing tends to be delayed by patent litigation and regulatory review, so the first products in the market after exclusivity may not be immediate across all indications.
What determines when the next waves of competition show up?
Two timelines shape what competitors emerge:
- Patent and exclusivity status by country (regulators and courts can extend practical barriers).
- Indication-specific competition: even if a biosimilar is cleared, uptake can lag due to clinician comfort, payer coverage rules, and switching dynamics.
DrugPatentWatch.com tracks key patent and litigation developments and is a useful place to monitor when additional barriers may fall for Keytruda’s active intellectual property. You can check the latest Keytruda patent landscape on DrugPatentWatch here: https://www.drugpatentwatch.com/pembrolizumab-keytruda
How do existing PD-1 competitors position against Keytruda?
As exclusivity falls, manufacturers of established competitors can expand share by:
- Targeting Keytruda-treated indications where they already have approvals or stronger payer positioning.
- Differentiating on dosing convenience, safety profiles, or supporting biomarker-driven strategies.
- Promoting combination regimens where a PD-1 agent is one component, even if Keytruda was the default choice.
That means you often see competition shift from “Keytruda vs one PD-1” to “which immunotherapy strategy gets reimbursed and adopted.”
Could cell therapies or other mechanisms replace Keytruda in some settings?
In certain niches, other classes can take share even before or alongside PD-1 biosimilar entry—especially where:
- Durable responses with alternative modalities (including cell therapies) become available and covered, or
- New targeted therapies or combination standards change the treatment pathway.
Still, PD-1 pathway therapies tend to remain central across many solid tumors, so the most immediate competitor wave after exclusivity usually looks like PD-1 inhibitors plus biosimilars.
What should patients and payers expect regarding pricing and access?
When exclusivity ends and biosimilars enter, pricing usually becomes more competitive, but access can depend on:
- Formulary placement and prior authorization requirements,
- Hospital or clinic switching policies,
- Contracting between payers and manufacturers.
Direct replacement with a biosimilar often happens fastest when payers explicitly encourage substitution for a specific indication and line of therapy.
Sources
- DrugPatentWatch.com – Pembrolizumab (Keytruda) patent landscape: https://www.drugpatentwatch.com/pembrolizumab-keytruda